Clinical Trials
Autism Spectrum Disorders (Pervasive Developmental Disorders)
Featured Studies
Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.
- Atomoxetine and Parent Management Training in Treating Children With Autism and Symptoms of Attention Deficit Disorder With Hyperactivity.
Interventional study. This study will evaluate the effectiveness of the medication atomoxetine, with and without parent management training, in treating children with autism or pervasive developmental disorder not otherwise specified who have symptoms of attention deficit hyperactivity disorder. Ages 5-14. Locations in Rochester, NY; Columbus, OH; Pittsburgh, PA.
- The Effect of Donepezil (AriceptĀ® (Registered Trademark)) on REM Sleep in Children With Autism.
Interventional study. This study will test whether donepezil (Aricept® (Registered Trademark)), a drug that is approved by the Food and Drug Administration to treat Alzheimer's disease, can increase rapid eye movement (REM) sleep in children with autism and autism spectrum disorder (ASD). Ages 2-10. Location in Bethesda, MD.
- Effectiveness of Atomoxetine in Treating Attention Deficit Hyperactivity Disorder Symptoms in Children and Adolescents With Autism.
Interventional study. This study will evaluate the effectiveness of atomoxetine in treating children with attention deficit hyperactivity disorder symptoms associated with autistic disorder, Asperger's syndrome, and pervasive developmental disorder, not otherwise specified. Ages 6-15. Location in Indianapolis, IN.
- Minocycline to Treat Childhood Regressive Autism.
Interventional study. There is a subgroup of children with autism that appears to develop typically for a period of time, and then loses social or language skills, or regresses. Ages 3-12. Locations in Washington, DC; Baltimore, MD; Bethesda, MD.
- Clinical and Immunological Investigations of Subtypes of Autism.
Evaluation study. The purpose of this study is to learn more about autism and its subtypes. Ages 1 Year-6. Location in Bethesda, MD.
- Screening for Studies on Autism Spectrum Disorders.
Evaluation study. This study will screen children and adolescents (and their parents) to determine the child's eligibility for participation in NIMH research studies on autism spectrum disorders, such as autism and Rett's Disorder. Ages 1 Year-20. Location in Bethesda, MD.
- Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders.
Interventional study. This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders. Ages 7-17. Location in Bethesda, MD.
- Long-Term Olanzapine Treatment in Children With Autism.
Interventional study. This study will determine the short- and long-term safety and effectiveness of the drug olanzapine (Zyprexa®) for reducing symptoms of autism in children. Ages 3-12. Location in Philadelphia, PA.
- Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism.
Interventional study. This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children. Ages 5-17. Location in Indianapolis, IN.
- Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children.
Interventional study. This study will first examine the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) and who do and do not have additional symptoms of attention deficit hyperactivity disorder (ADHD). Ages 7-12. Location in Houston, TX.